Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling

Fig. 2

circRNA-SORE is vital for sustaining sorafenib resistance. a qPCR analysis of circRNA-SORE in four HCC sorafenib-resistant cell lines with and without si-circRNA-SORE under sorafenib treatment for 72 h. b Relative cell viability of four HCC sorafenib-resistant cell lines with and without si-circRNA-SORE under sorafenib treatment for 72 h. c Images of colony formation assay wells for three HCC sorafenib-resistant cell lines and their parental cell lines with and without si-circRNA-SORE under sorafenib treatment for 72 h. d Wild-type HCC cells and sorafenib-resistant cells transfected with si-circRNA-SORE or negative control siRNA (si-NC) were treated with sorafenib. Cell viability was recorded by the Real-time Cell Analysis xCELLigence System. ΔAUC (difference in the area under curve) = (AUC NC) – (AUC si-SORE). e Analysis of apoptosis in HepG2-SR, SKhep1-SR and Huh7-SR cells with or without si-circRNA-SORE by JC-1 assays. f Kaplan-Meier survival analysis for HCC patients with low and high circRNA-SORE expression. Low and high circRNA-SORE expression was cut off by the median expression. g Kaplan-Meier survival analysis for HCC patients treated with Sorafenib with low and high circRNA-SORE expression. The low and high circRNA-SORE expression was cut off by the median expression. p < 0.05 was considered statistically significant. Three different independent experiments with three technical repetitions were performed. Data are expressed as the mean ± SEM. Statistical analyses used Student’s t-test and Kaplan-Meier survival analysis. p < 0.05 was considered statistically significant. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001

Back to article page